Concord Drugs Limited (BOM:538965)

Concord Drugs Statistics

Total Valuation

Concord Drugs has a market cap or net worth of INR 962.04 million. The enterprise value is 1.15 billion.

Market Cap	962.04M
Enterprise Value	1.15B

Important Dates

The last earnings date was Saturday, February 14, 2026.

Earnings Date	Feb 14, 2026
Ex-Dividend Date	n/a

Share Statistics

Concord Drugs has 13.18 million shares outstanding. The number of shares has increased by 25.47% in one year.

Current Share Class	13.18M
Shares Outstanding	13.18M
Shares Change (YoY)	+25.47%
Shares Change (QoQ)	+33.87%
Owned by Insiders (%)	66.79%
Owned by Institutions (%)	n/a
Float	4.38M

Valuation Ratios

The trailing PE ratio is 160.63.

PE Ratio	160.63
Forward PE	n/a
PS Ratio	1.88
PB Ratio	2.80
P/TBV Ratio	2.80
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	203.22
EV / Sales	2.24
EV / EBITDA	28.59
EV / EBIT	42.84
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.56
Debt / EBITDA	4.76
Debt / FCF	n/a
Interest Coverage	1.47

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	3.64%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	6.67%
Revenue Per Employee	2.05M
Profits Per Employee	22,632
Employee Count	250
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Concord Drugs has paid 2.18 million in taxes.

Income Tax	2.18M
Effective Tax Rate	27.79%

Stock Price Statistics

The stock price has increased by +137.97% in the last 52 weeks. The beta is 0.43, so Concord Drugs's price volatility has been lower than the market average.

Beta (5Y)	0.43
52-Week Price Change	+137.97%
50-Day Moving Average	80.19
200-Day Moving Average	64.98
Relative Strength Index (RSI)	39.05
Average Volume (20 Days)	9,928

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Drugs had revenue of INR 512.41 million and earned 5.66 million in profits. Earnings per share was 0.45.

Revenue	512.41M
Gross Profit	93.90M
Operating Income	26.84M
Pretax Income	7.84M
Net Income	5.66M
EBITDA	40.21M
EBIT	26.84M
Earnings Per Share (EPS)	0.45

Balance Sheet

The company has 3.65 million in cash and 191.42 million in debt, with a net cash position of -187.77 million or -14.25 per share.

Cash & Cash Equivalents	3.65M
Total Debt	191.42M
Net Cash	-187.77M
Net Cash Per Share	-14.25
Equity (Book Value)	344.19M
Book Value Per Share	33.99
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 18.32%, with operating and profit margins of 5.24% and 1.10%.

Gross Margin	18.32%
Operating Margin	5.24%
Pretax Margin	1.53%
Profit Margin	1.10%
EBITDA Margin	7.85%
EBIT Margin	5.24%
FCF Margin	n/a

Dividends & Yields

Concord Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-25.47%
Shareholder Yield	-25.47%
Earnings Yield	0.59%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1